Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT04150965 |
Title | Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase Ib/II |
Variant Requirements | No |
Sponsors | Multiple Myeloma Research Consortium |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
Emory University | Atlanta | Georgia | 30322 | United States | Details | |
Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02115 | United States | Details | |
Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | United States | Details | |
University of Michigan | Ann Arbor | Michigan | 48109 | United States | Details | |
Washington University School of Medicine Division of Medical Oncology | Saint Louis | Missouri | 63110 | United States | Details | |
Hackensack Meridian Medical Center | Hackensack | New Jersey | 07601 | United States | Details | |
Mount Sinai School of Medicine | New York | New York | 10029 | United States | Details | |
Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | United States | Details | |
Levine Cancer Institute | Charlotte | North Carolina | 28204 | United States | Details | |
UT Southwestern Medical Center | Dallas | Texas | 75390 | United States | Details |